Pharmaceutical | Tokio X'press - Part 102

Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108

Daiichi Sankyo Terminates Deve

Friday September 1st, 2017By Tokio X'press JPN, Pharmaceutical daiichisankyo

Daiichi Sankyo Terminates Deve

Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD SUMITOMO DAINIPPON PHARMA Co., Ltd

Sunovion Submits

Friday September 1st, 2017By Tokio X'press FDA, JPN SUMITOMO DAINIPPON PHARMA

Sunovion Submits

Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan News Release 20170901

Ono and Seikagaku Reach a Defi

Friday September 1st, 2017By Tokio X'press JPN, Pharmaceutical ONO

Ono and Seikagaku Reach a Defi

Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indications of Advanced Renal Cell Carcinoma, Relapsed or Progressed Classical Hodgkin Lymphoma, Recurrent or Metastatic Head and Neck, Locally Advanced or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma in Combination with Ipilimumab in South Korea News Release 20170830

Opdivo® (Nivolum

Thursday August 31st, 2017By Tokio X'press Pharmaceutical ONO

Opdivo® (Nivolum

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer

FDA Grants Breakthrough Therap

Wednesday August 30th, 2017By Tokio X'press FDA, JPN Daiichi Sankyo

FDA Grants Breakthrough Therap